Researchers publishing in Nature Medicine on 1 September 2026 reported that lower early-pregnancy levels of isthmin-2, or ISM2, may help predict preeclampsia and fetal growth restriction. The finding could open the door to earlier identification of pregnancies at higher risk, giving clinicians more time to monitor patients and consider timely intervention.
What the study found
The authors said their analysis of serum proteomics from pregnancy cohorts showed ISM2 is involved in extravillous trophoblast invasion, a process central to placental development. In the study, lower maternal serum levels of ISM2 in early pregnancy were associated with a higher risk of preeclampsia and fetal growth restriction. The paper was published as an article open access on 1 September 2026.
Preeclampsia and fetal growth restriction remain major causes of maternal and fetal complications, and the new work adds another possible biomarker to the search for earlier detection. The researchers said the result points to a biological role for ISM2 rather than a simple statistical association, strengthening interest in whether the marker could be used in future screening strategies.
Why it matters for maternity care
Early prediction is one of the biggest challenges in maternity medicine because both conditions can progress before obvious symptoms appear. If validated in larger studies, an early blood-based marker could help clinicians identify patients who may benefit from closer surveillance during pregnancy. That could be especially relevant in settings where access to specialist monitoring is limited or where risk stratification needs to happen sooner.
The findings are also likely to interest UK clinicians and researchers because preeclampsia and fetal growth restriction remain important causes of pregnancy-related morbidity. While the study does not by itself change practice, it adds to a growing body of work aimed at moving obstetric care toward earlier and more precise risk detection.
What happens next
The Nature Medicine publication does not claim the biomarker is ready for routine use. Instead, it highlights a promising research direction that would need further validation before any clinical application. Larger cohorts, replication studies and practical testing would be required before ISM2 could be considered for screening in real-world maternity care.
For now, the new report offers a clearer view of the biology behind these pregnancy complications and suggests that the earliest stages of pregnancy may hold clues to later risk. If future studies confirm the findings, ISM2 could become part of a broader toolkit for earlier detection and better pregnancy outcomes.
Photo source: AI-generated or edited image
